Steve Gleason's Current Health Status and Medical Background
Steve Gleason is alive and continues to live with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. He was diagnosed with ALS in January 2011, which is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. Gleason's diagnosis came after he retired from professional football, and he has since become one of the most visible advocates for ALS research and awareness globally.
Despite the progression of ALS, Gleason remains actively engaged in public life through his foundation, Team Gleason, and various technology initiatives. He uses eye-tracking technology and other assistive devices to communicate and manage his daily activities. His public appearances and social media updates consistently reflect his ongoing battle with the disease, demonstrating that ALS does not define the entirety of his life trajectory.
Post-Football Career and Financial Ventures
Investment Activities and Business Interests
After retiring from the National Football League, Gleason transitioned into a career focused on advocacy and investment. His financial activities include involvement in technology startups and real estate ventures, though specific portfolio details are not publicly disclosed in full. He has leveraged his public profile to attract partnerships and funding for his nonprofit initiatives.
Team Gleason, the nonprofit organization he founded, has received significant funding from corporate partners and individual donors. The organization's financial transparency reports indicate a focus on assistive technology grants and advocacy campaigns. Gleason's ability to sustain these operations relies on a combination of personal resources and external fundraising, with his net worth estimated in the low millions based on public records and media reports.
Recent Public Activities and Advocacy Milestones
Technology and Accessibility Projects
Gleason has been a vocal proponent of using technology to improve quality of life for people with ALS. He has partnered with companies developing eye-tracking communication devices and home automation systems. These collaborations have resulted in publicly documented case studies showing how customized tech setups can extend independent living capabilities for ALS patients.
His advocacy has influenced legislative and corporate policies regarding accessibility. Gleason has met with lawmakers to discuss insurance coverage for assistive technologies and has participated in high-profile campaigns for ALS research funding. His work continues to be recognized by major organizations, and he remains a central figure in the ALS community, regularly updating his public channels with current project developments and health milestones.